Table 4.
Weibull Proportional Hazards Model Examining Time to Tuberculosis Diagnosis After HAART Initiation
| Univariate model |
Multivariate model adjusted for cohort |
||||
| Events3(Person-years) | Relative hazard (95% CI) | P value | Relative hazard (95% CI) | P value | |
| Age (per year) | 145 (199779) | 0.88 (.73–1.05) | .16 | 0.89 (.73–1.08) | .23 |
| Male sex | 104 (152392) | 0.79 (.55–1.13) | .20 | 0.96 (.64–1.43) | .83 |
| Race | |||||
| Black—Canada | 13.6 (5232.5) | 5.92 (3.05–11.48) | <.001 | 14.02 (2.73–72.0) | .002 |
| Black—USA | 55.0 (60130.0) | 2.07 (1.38–3.09) | <.001 | 1.57 (.99–2.48) | .053 |
| Hispanic | 26.1 (28606) | 2.09 (1.25–3.50) | .005 | 2.29 (1.35–3.89) | .002 |
| Other | 7.8 (6587.6) | 2.74 (1.21–6.19) | .015 | 2.68 (1.17–6.15) | .020 |
| White | 42.4 (99223) | 1.0 | … | 1.0 | … |
| IDU | 46.4 (43910) | 1.63 (1.15–2.33) | .007 | 1.71 (1.15–2.55) | .008 |
| HAART type | |||||
| PI based | 84 (121542) | 1.0 | 1.0 | … | |
| NNRTI | 48 (54813) | 1.16 (.82–1.66) | .40 | 1.19 (.82–1.73) | .37 |
| Other2 | 13 (23424) | 0.76 (.43–1.37) | .37 | 0.78 (.43–1.41) | .40 |
| Antiretroviral therapy naive (yes vs no) | 92 (104531) | 1.46 (1.03–2.05) | .03 | 1.23 (.85–1.80) | .28 |
| CD4 | |||||
| 0<CD4≤50 | 37.1 (34645) | 2.48 (1.47–4.20) | <.001 | 2.10 (1.21–3.64) | .009 |
| 50<CD4≤100 | 27.2 (22437) | 2.83 (1.60–5.02) | <.001 | 2.47 (1.36–4.49) | .003 |
| 100<CD4≤200 | 37.6 (41866) | 2.10 (1.29–3.40) | .003 | 1.90 (1.16–3.12) | .011 |
| CD4 > 200 | 43.1 (100831) | 1.0 | … | 1.0 | … |
| log10(HIV RNA)1 | 145 (199779) | 1.26 (1.03–1.53) | .02 | 1.05 (.85–1.31) | .64 |
| Year of HAART Initiation (per year) | 145 (199779) | 1.04 (.98–1.10) | .19 | 1.01 (.95–1.08) | .74 |
NOTE. CI, confidence interval; HAART, highly active anitretroviral therapy; IDU, injection drug use as HIV risk factor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, HIV-1 protease inhibitor.
1
Value prior to HAART initiation. Multiple imputation was used for missing values for CD4 and HIV RNA.
2
Other corresponds to those who had PI and NNRTI, 3+ NRTI, or an entry/fusion inhibitor based regimen.
3
Mean number of events and person-years are presented for categories that are affected by multiple imputation resulting in non-integer values for the number of TB events.